News & Events
News & Events

Shenzhen University develops the world's first single-agent chemiluminescence COVID-19 antibody detection kit

On the evening of February 10th, single agent chemiluminescence covid-29 antibody detection kit was jointly developed by Shenzhen University, Shenzhen Third People's Hospital (National Infectious Diseases Clinical Research Center) and The Trueturn-Biological Technology Co. Ltd and it has been successfully tested in the Third People's Hospital of Shenzhen. Different from (viral) nucleic acid testing, this kit can rapidly diagnose the COVID-19 infection in 22 minutes by detecting novel coronavirus-specific IgM / IgG antibodies in the blood of infected persons.

At present, the samples collected for nucleic acid testing of suspected cases of novel coronavirus are mostly upper respiratory tract samples (mainly throat swabs), and it is extremely risky for medical personnel to be exposed to the virus during the collection process. The reason for using serum or plasma as test samples in the chemiluminescence COVID-19 IgM and IgG antibody detection kit developed this time, is that blood samples are easily collected and generally, blood samples have hardly a trace of the virus, which can greatly reduce the risk of infection for medical staff. At the same time, the test results can be obtained in 22 minutes, which can also save the complicated procedures of testing the samples in the laboratory. In other words, the use of the detection kit is simple, it can protect the safety of medical staff and it greatly relieves the huge work pressure of staff carrying out clinical diagnosis and treatment.

Chen Xinchun, deputy director of Shenzhen University Medical Department, emphasized that the test kit developed this time is to detect antibodies produced by the patients ' immune system in response to the virus, not to test the virus itself (such as viral nucleic acid). At least 90 patients have been tested positive for the novel coronavirus pneumonia in the Third People's Hospital of Shenzhen (National Center for Clinical Research of Infectious Diseases). Preliminary clinical trial results after the use of the newly developed test kit show that in the 90 clinical samples (including 21 cases that tested negative), the IgM compliance rate was 95.5% (86/90), and the IgG clinical compliance rate was 96.7% (87/90). Researchers will set out to collect more clinical samples for large-scale validation.

Previously, the virology research team of Shenzhen University, the Third People's Hospital of Shenzhen, and Shenzhen Uni-Medica Co., Ltd, jointly developed a rapid pathogen detection kit for multiple (15) respiratory tract, which can give the differential diagnosis of suspected disease in 90 minutes. Tests done in the period up to January 31 show that, compared with the test results from the government, the number of cases that tested positive is the same, whereas among 20% of the cases that tested negative, other viral infections were detected.